Cepheid, a molecular diagnostics subsidiary of Danaher Corporation, has announced a strategic collaboration with Oxford Nanopore Technologies PLC. The partnership aims to develop and commercialize seamless end-to-end workflows for sequencing-based infectious disease solutions.
A successful proof-of-concept study has already demonstrated the feasibility of integrating Cepheid's cartridge-based GeneXpert system for sample and library preparation with Oxford Nanopore's molecular analysis platform. This integration promises rapid, information-rich sequencing.
The companies plan to launch a joint research use only workflow that will enable customers to perform in-house infectious disease analysis, delivering results within hours instead of days. This advancement is positioned for future expansion into scaled routine clinical use.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.